Metformin plus lifestyle interventions can prevent diabetes in people with impaired glucose tolerance, treat type 2 diabetes ...

By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes ...

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

In a groundbreaking move, Eli Lilly (NYSE:LLY) is set to test its weight-loss medications on individuals who are not ...

Aurobindo Pharma receives USFDA approval for Cephalexin tablets, expected to launch in Q3FY25 with CGT designation.

Aurobindo Pharma gains FDA approval for Cephalexin Tablets, bioequivalent to Keflet, with CGT designation and shared exclusivity.

The startup will be headed by CEO Ron Renaud, who previously led Cerevel Therapeutics — a developer of drugs for neurological conditions — and oversaw its acquisition by AbbVie in an $8.7 billion deal ...

Kailera Therapeutics launched on Tuesday as the latest startup seeking a slice of the booming market for anti-obesity therapies with a rare $400 million in early-stage funding. Headed by CEO Ron ...

Six 2025 Lilly Endowment Community Scholar finalists have been selected by the Steuben County Community Foundation, it was ...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Corp. with ...

Eli Lilly is considering testing its blockbuster weight-loss drugs in people who are not overweight but are at risk of weight ...

Plus: Adam Frisch and Jeff Hurd debate for a second time. State-level super PAC spending on legislative races.